BRWCX
Price
$21.28
Change
-$0.51 (-2.34%)
Updated
Sep 6 closing price
GFACX
Price
$61.91
Change
-$1.33 (-2.10%)
Updated
Sep 6 closing price
Ad is loading...

BRWCX vs GFACX

Header iconBRWCX vs GFACX Comparison
Open Charts BRWCX vs GFACXBanner chart's image
MFS Blended Research Growth Eq C
Price$21.28
Change-$0.51 (-2.34%)
VolumeN/A
CapitalizationN/A
American Funds Growth Fund of Amer C
Price$61.91
Change-$1.33 (-2.10%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
BRWCX vs GFACX Comparison Chart
Loading...
VS
BRWCX vs. GFACX commentary
Sep 07, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRWCX is a Buy and GFACX is a Buy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 270B vs. BRWCX (337M). BRWCX pays higher dividends than GFACX: BRWCX (0.12) vs GFACX (0.00). BRWCX was incepted earlier than GFACX: BRWCX (9 years) vs GFACX (24 years). BRWCX is a more actively managed with annual turnover of: 64.00 vs. GFACX (31.00). GFACX has a lower initial minimum investment than BRWCX: GFACX (250) vs BRWCX (1000). BRWCX annual gain was more profitable for investors over the last year : 27.68 vs. GFACX (16.44). BRWCX return over 5 years is better than : 53.67 vs. GFACX (38.56).
BRWCXGFACXBRWCX / GFACX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years24 years-
Gain YTD18.10314.982121%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets337M270B0%
Annual Yield % from dividends0.120.00-
Returns for 1 year27.6816.44168%
Returns for 3 years-2.59-11.0823%
Returns for 5 years53.6738.56139%
Returns for 10 yearsN/A42.46-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KW11.040.03
+0.27%
Kennedy-Wilson Holdings
CTVA55.11-0.39
-0.70%
Corteva
FIVN29.58-0.24
-0.80%
Five9
VEV0.14N/A
-1.68%
Vicinity Motor Corp
ADAP1.11-0.05
-4.31%
Adaptimmune Therapeutics plc